Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2006 1
2008 1
2010 1
2013 4
2014 1
2018 2
2019 1
2021 2
2022 1
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.
Sherman MA, Yang Q, Gutierrez-Alamillo L, Pak K, Flegel WA, Mammen AL, Rider LG, Casciola-Rosen LA; Childhood Myositis Heterogeneity Collaborative Study Group. Sherman MA, et al. Arthritis Rheumatol. 2024 Apr;76(4):631-637. doi: 10.1002/art.42768. Epub 2024 Jan 30. Arthritis Rheumatol. 2024. PMID: 38059274
Autoantibodies Recognizing Specificity Protein 4 Co-occur With Anti-Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis.
Sherman MA, Pak K, Pinal-Fernandez I, Flegel WA, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group. Sherman MA, et al. Arthritis Rheumatol. 2023 Sep;75(9):1668-1677. doi: 10.1002/art.42512. Epub 2023 Jul 19. Arthritis Rheumatol. 2023. PMID: 36996276 Free PMC article.
Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features.
Sherman MA, Graf R, Sabbagh SE, Galindo-Feria AS, Pinal-Fernandez I, Pak K, Kishi T, Flegel WA, Targoff IN, Miller FW, Lundberg IE, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group. Sherman MA, et al. Rheumatology (Oxford). 2023 Feb 23;62(SI2):SI226-SI234. doi: 10.1093/rheumatology/keac428. Rheumatology (Oxford). 2023. PMID: 35961028 Free PMC article.
Anti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis.
Pinal-Fernandez I, Pak K, Gil-Vila A, Baucells A, Plotz B, Casal-Dominguez M, Derfoul A, Martinez-Carretero MA, Selva-O'Callaghan A, Sabbagh S, Casciola-Rosen L, Albayda J, Paik J, Tiniakou E, Danoff SK, Lloyd TE, Miller FW, Rider LG, Christopher-Stine L, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group. Pinal-Fernandez I, et al. Arthritis Rheumatol. 2022 Feb;74(2):358-364. doi: 10.1002/art.41931. Epub 2021 Dec 26. Arthritis Rheumatol. 2022. PMID: 34313394 Free PMC article.
The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.
Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, Rider LG; with the Childhood Myositis Heterogeneity Collaborative Study Group. Shah M, et al. Medicine (Baltimore). 2013 Jan;92(1):25-41. doi: 10.1097/MD.0b013e31827f264d. Medicine (Baltimore). 2013. PMID: 23263716 Free PMC article.
18 results